Screening for prostate cancer becomes more complex in men over the age of 70. The US Preventive Services Task Force (USPSTF) currently recommends against routine PSA testing in this age group. The PSA ...
A recent abstract published in Nature Communications outlines a new, easy-to-use tool that could help guide early treatment discussions for people with mHSPC. In a nutshell, the innovative system ...
Convergent Therapeutics Inc., a clinical-stage biotechnology company developing next-generation alpha-emitting radioantibodies for the treatment of advanced prostate cancer, today announced that ...
Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that the first patient has been dosed in one of three expansion cohorts in the Phase 1 trial evaluating VIR-5500, a prostate-specific membrane ...
In patients with BRCA2-mutated mCSPC, treatment with Akeega significantly reduced the risk of radiographic progression or death by 54%. The Food and Drug Administration (FDA) has approved Akeega ® ...
Liquid biopsy enables genomic profiling in prostate cancer with high success rates. Learn more about its potential as a ...
Artera has secured CE marking under the European Union In Vitro Diagnostic Regulation (EU IVDR) for its ArteraAI prostate ...
The Israeli leader had surgery in 2024 for an enlarged prostate. More recently, follow-up care detected a tumor, his office ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results